DAX®15.669,29+1,00%TecDAX®3.668,39+0,54%Dow Jones 3035.061,55+0,68%Nasdaq 10015.111,79+1,15%
finanztreff.de

EQS-News: Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19

| Quelle: Dow Jones Newsw... | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen

EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study results
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the
Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
2021-06-16 / 07:00
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the
Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
Geneva, Switzerland, June 16, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a
biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development to treat
COVID-19-induced respiratory disorders, reported today that its collaboration partner, NRx Pharmaceuticals, Inc.,
(Nasdaq: NRXP) ("NRx") has announced additional results from the aviptadil U.S. Expanded Access Protocol (EAP). The EAP
included 240 patients in the intensive care unit (ICU) with critical COVID-19 respiratory failure requiring either
invasive or non-invasive mechanical ventilation, or high flow rate oxygen by[]nasal cannula, and not eligible for the
recently completed phase 2b/3 clinical trial with IV aviptadil. According to NRx's press release, these EAP data are
being submitted by NRx to the U.S. Food and Drug Administration (FDA) as "real world" evidence in support of the
findings from the phase 2b/3 trial. The related NRx press release can be accessed through the following link.
###
ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in
human patients or a strong scientific rationale. Relief's lead drug candidate RLF-100^TM (aviptadil), a synthetic form
of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical development in the U.S. for the treatment of
respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered
into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization
of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate
(NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB
under the symbol RLFTF. For more information, visit www.relieftherapeutics.com.
Follow us on LinkedIn.

CONTACT: FOR MEDIA/INVESTOR INQUIRIES:
RELIEF THERAPEUTICS Holding AG MC Services AG
Jack Weinstein Anne Hennecke
Chief Financial Officer and Treasurer Tel.: +49 (0) 211-529-252-22
Mail: contact@relieftherapeutics.com Mail: relief@mc-services.eu

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, and there can be no assurance that NRx's application for EUA will be approved by the FDA or that Relief will be successful in obtaining approval for the product in Europe or other territories. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and do not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

End of Media Release


Language: English
Company: RELIEF THERAPEUTICS Holdings AG
Avenue de Sécheron 15
1202 Genève
Switzerland
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Listed: SIX Swiss Exchange
EQS News ID: 1208382

End of News EQS Group News Service

1208382 2021-06-16



Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1208382&application_name=news


(END) Dow Jones Newswires

June 16, 2021 01:01 ET ( 05:01 GMT)
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:

Aktuelle Videos

HSBC Trading TV

Werbung

Trading-Tipp

Börsen & Märkte

US-Marktüberblick

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 30 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen